Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 84 Breast Neoplasms 10 Neoplasm Metastasis 7 Neoplasms 5 Prostatic Neoplasms, Castration-Resistant 4 Prostate Cancer Metastatic 4 Metastatic Castration-Resistant Prostate Cancer 4 Metastatic Castration-resistant Prostate Cancer 3 Castration-resistant Prostate Cancer 3 Triple Negative Breast Neoplasms 2 Castration Resistant Metastatic Prostate Cancer 2 Adenocarcinoma of the Prostate 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Salivary Cancer 1 Recurrent Endometrial Endometrioid Adenocarcinoma 1 Prostatic Diseases 1 Prostate Carcinoma Metastatic to the Bone 1 Prostate Adenocarcinoma 1 Primary Breast Cancer ER+ve 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Non-metastatic, Hormone naïve Prostate Cancer 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoadjuvant Therapy 1 NSCLC Harboring NRG1 Fusion 1 Metastatic Progressive Castration-resistant Prostate Cancer 1 Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Primary Breast Cancer ER+ve × enzalutamide × Clear all

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡